Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24241700 | 1.00 | CA1 (0.40) | CA1CA2CA9GGPS1CA12 | |
| SCHEMBL22877813 | 1.00 | CA1 (0.40) | CA1CA2CA9GGPS1CA12 | |
| SCHEMBL23542126 | 1.00 | CA1 (0.40) | CA1CA2CA9GGPS1CA12 | |
| SCHEMBL27369142 | 0.90 | CA1 (0.36) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3863645 | 0.87 | CA1 (0.35) | CA1CA2CA9GGPS1CA12 | |
| SCHEMBL25907572 | 0.86 | CA1 (0.33) | CA1CA2CA9CA12CA7 | |
| SCHEMBL23481720 | 0.83 | GGPS1 (0.41) | GGPS1FAAHFDPS | |
| SCHEMBL21316539 | 0.81 | GGPS1 (0.40) | CA2GGPS1FAAHFDPS | |
| SCHEMBL12669288 | 0.81 | GGPS1 (0.40) | GGPS1FAAHFDPS | |
| SCHEMBL23475303 | 0.79 | GGPS1 (0.43) | CA1CA2GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183274-A1 | SCALABLE POLYPROPIONATE LACTONE STEREOTETRADS | AKANOCURE PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-10851121-B2 | Scalable polypropionate lactone stereotetrads | AKANOCURE PHAMRACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183274-A1 | SCALABLE POLYPROPIONATE LACTONE STEREOTETRADS | SBDS, STS, ADCYAP1R1 | CA1 863/4885CA2 1952/4885CA9 739/4885 |
| US-10851121-B2 | Scalable polypropionate lactone stereotetrads | SBDS, STS, ADCYAP1R1 | CA1 863/4885CA2 1952/4885CA9 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.